PCN68 US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
Abstract
Authors
C Chin S Jones S Verma L Bernard MF Thompson N Mittmann BCF Chan M Tangirala L Asmar